发明名称 |
Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Events caused by CD3-Specific Binding Domains |
摘要 |
The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated. |
申请公布号 |
US2014227272(A1) |
申请公布日期 |
2014.08.14 |
申请号 |
US201414176091 |
申请日期 |
2014.02.08 |
申请人 |
AMGEN RESEARCH (MUNICH) GMBH |
发明人 |
Kufer Peter;Nagorsen Dirk;Scheele Juergen;Zugmaier Gerhard;Klinger Matthias;Hoffmann Patrick;Naegele Virginie;Dopfer Elaine-Pashupati |
分类号 |
C07K16/28;G01N33/50;A61K31/65;A61K31/10;A61K39/395;C07K16/18 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
1. A compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. |
地址 |
Munich DE |